Skip to content

Source filing unavailable

Q4 2023 · —

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$12.44Mderivedno prior Q4 2022 on fileN/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$8,036,000—
Free Cash Flowderived-$8,472,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q4 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR